SCR-A0011 / Simcere - LARVOL DELTA

SCR-A0011, a novel bispecific ADC targeting cMET and B7H3, exhibits potent anti-tumor efficacy (AACR 2025) - "These findings illustrated SCR-A011 could be a potential First-in-Class BsADC to conquer the resistance or non-response of current treatment in broad cancer types and may provide a new therapeutic approach for B7H3 and cMET positive cancer patients in the future."

Clinical • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CD276